TIBER CREEK GROUP

Lobbying for JAZZ PHARMACEUTICALS · â€‹Biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $50,000.00 income · posted Apr 19, 2025

Lobbying activity 3

Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxifying hemp.

Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

Budget/Appropriations

Appropriations issues related to House Ag/FDA Appropriations bill pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Ag/ FDA amendment - technical correction to the 2025 Ag/ FDA appropriations bill related to hemp; Issues related to intoxifying hemp products.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.